Compare FENG & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | CYCN |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 16.6M |
| IPO Year | 2011 | 2019 |
| Metric | FENG | CYCN |
|---|---|---|
| Price | $1.50 | $3.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.8K | ★ 36.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $1.39 | $1.03 |
| 52 Week High | $3.65 | $8.48 |
| Indicator | FENG | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 58.67 |
| Support Level | $1.50 | $2.93 |
| Resistance Level | $1.80 | $4.47 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 46.67 | 56.17 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.